MaxWell Biosystems AG is advancing its global go-to-market strategy with the establishment of a dedicated EMEA regional team, expanding its presence and partnerships across Europe, the Middle East, and Africa.

A Nature study presents a human iPSC-derived neuronal network model that reveals how TDP-43 dysfunction drives neurotoxicity in ALS/FTLD and highlights NPTX2 as a promising therapeutic target. Using MaxWell Biosystems' MaxOne HD-MEAs, the team captured high-resolution functional readouts of these networks, supporting detailed characterization from network down to single-cell features.